Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
4/2023
vol. 125 abstract:
Guidelines/recommendations
Position Statement of the Polish Society of Ophthalmology establishing standards for the management of patients with exudative age-related macular degeneration
Marta Misiuk-Hojło
1
,
Alina Bakunowicz-Łazarczyk
2
,
Dariusz Dobrowolski
3
,
Iwona Grabska-Liberek
4
,
Jerzy Mackiewicz
5
,
Ewa Mrukwa-Kominek
6
,
Agnieszka Nowak
7
,
Weronika Pociej-Marciak
7
,
Bożena Romanowska-Dixon
7, 8
,
Marcin Stopa
9
,
Jacek Szaflik
10
,
Jakub Kałużny
11
,
Joanna Adamiec-Mroczek
1
KLINIKA OCZNA 2023, 125, 4: 181-189
Online publish date: 2023/12/22
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Age-related macular degeneration (AMD) is a leading cause of impairment of vision in the population over 50 years of age in developed countries. The most important risk factors for the development of AMD include increasing age, living in northern regions of Europe, genetic factors and smoking. The recommendations support the use of supplements (antioxydants), intravitreal injection of anti-VEGF agents and photodynamic therapy (PDT). Anti-VEGF therapy (e.g., aflibercept, bevacizumab, ranibizumab, brolucizumab, faricimab) is the most effective way to manage neovascular AMD and represents the first line of treatment. In patients with neovascular AMD, early detection and prompt treatment improves the visual outcome. This paper presents the current treatment standards for neovascular AMD developed by a group of experts from the Polish Ophthalmological Society.
keywords:
age related macular degeneration, anti-VEGF therapy, retina, treatment guidelines |
|